<div id="readability-page-1"><p>Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) Director Floyd Petersen sold 1,737 shares of the firm's stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $25.69, for a total transaction of $44,623.53. Following the completion of the transaction, the director directly owned 73,794 shares in the company, valued at approximately $1,895,767.86. The trade was a 2.30% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.</p><h2>Amphastar Pharmaceuticals Trading Up 4.1%</h2><ul><li>Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts</li></ul><p>Shares of NASDAQ:AMPH traded up $1.04 during midday trading on Monday, hitting $26.31. The company had a trading volume of 472,889 shares, compared to its average volume of 527,280. The company has a current ratio of 3.12, a quick ratio of 2.21 and a debt-to-equity ratio of 0.78. Amphastar Pharmaceuticals, Inc. has a 12 month low of $20.39 and a 12 month high of $42.49. The firm has a fifty day simple moving average of $25.52 and a 200 day simple moving average of $25.66. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of 11.64, a PEG ratio of 7.08 and a beta of 0.91. </p><p>Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.83 by $0.10. The firm had revenue of $191.84 million for the quarter, compared to analyst estimates of $186.90 million. Amphastar Pharmaceuticals had a return on equity of 19.70% and a net margin of 15.43%. On average, analysts predict that  Amphastar Pharmaceuticals, Inc. will post 3.49 EPS for the current year. </p><h2>Analyst Upgrades and Downgrades</h2><ul><li>Promising Small Biotech Amphastar Sees Actionable Pullback </li></ul><p>Several research firms have weighed in on AMPH. Barclays initiated coverage on shares of Amphastar Pharmaceuticals in a report on Tuesday, December 9th. They issued an &#34;equal weight&#34; rating and a $30.00 target price on the stock. Needham &amp; Company LLC dropped their price target on Amphastar Pharmaceuticals from $36.00 to $34.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, November 7th. Weiss Ratings  reiterated a &#34;hold (c)&#34; rating on shares of Amphastar Pharmaceuticals in a report on Monday, December 8th. Bank of America increased their target price on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a &#34;neutral&#34; rating in a research note on Tuesday, August 26th. Finally, Zacks Research lowered shares of Amphastar Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Friday, November 14th. Two research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Amphastar Pharmaceuticals  has a consensus rating of &#34;Hold&#34; and an average price target of $31.00.</p><p><b>Get Our Latest Analysis on Amphastar Pharmaceuticals</b></p><h2>Institutional Inflows and Outflows</h2><p>A number of hedge funds have recently added to or reduced their stakes in AMPH. FNY Investment Advisers LLC acquired a new position in shares of  Amphastar Pharmaceuticals during the 3rd quarter worth about $26,000.  Danske Bank A S bought a new stake in  Amphastar Pharmaceuticals during the third quarter worth about $614,000.  Quarry LP bought a new stake in  Amphastar Pharmaceuticals during the third quarter worth about $32,000.  Millennium Management LLC boosted its position in  Amphastar Pharmaceuticals by 12.7% during the third quarter. Millennium Management LLC now owns 697,765 shares of the company's stock valued at $18,595,000 after purchasing an additional 78,781 shares during the last quarter.  Finally, Lighthouse Investment Partners LLC bought a new position in  Amphastar Pharmaceuticals in the third quarter valued at approximately $576,000. Institutional investors own  65.09% of the company's stock. </p><h2>Amphastar Pharmaceuticals Company Profile</h2> (Get Free Report)<p>Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Amphastar Pharmaceuticals</li><li>How to Calculate Return on Investment (ROI)</li><li>ServiceNow’s $7 Billion Gamble: Panic or Opportunity?</li><li>Following Congress Stock Trades</li><li>Dell and HP Are Raising Prices—And Investors Should Take Note</li><li>The Most Important Warren Buffett Stock for Investors: His Own</li><li>Why DLocal Is the Top Emerging Market Fintech Stock to Watch for 2026</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1QSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1QSA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Amphastar Pharmaceuticals Right Now?</h2><p>Before you consider Amphastar Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.</p><p>While Amphastar Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AMPH

<p>Amphastar Pharmaceuticals Director Floyd Petersen sold 1,737 shares for $44,623.53, reducing his ownership by 2.30%. The sale was disclosed in an SEC filing. Amphastar's stock rose 4.1% to $26.31, with a market cap of $1.21 billion. Analysts have mixed ratings, with a consensus "Hold" and a $31.00 average price target. Institutional investors own 65.09% of the stock.</p>

Amphastar Pharmaceuticals (NASDAQ:AMPH) Director Sells $44,623.53 in Stock